Blog

Biden administration to impose inflation penalties on dozens of drugs

reuters | December 14, 2023

By Andrea Shalal BETHESDA, Md. (Reuters) -The Biden administration said on Thursday it had identified 48 drugs in the Medicare program whose prices rose quicker than inflation during the fourth quarter of the year and may require their makers to pay rebates. President Joe Biden’s signature Inflation Reduction Act (IRA) includes a provision to penalize […]

Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies

reuters | December 1, 2023

By Patrick Wingrove (Reuters) -Novo Nordisk said on Thursday it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%. The Danish drugmaker said it found impurities in all the drugs […]

Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug

reuters | November 21, 2023

By Brendan Pierson (Reuters) -Texas Attorney General Ken Paxton accused Pfizer and its supplier Tris Pharma of providing children’s ADHD medicine that it knew might be ineffective to the state’s Medicaid insurance program for low-income people, in a lawsuit unsealed on Monday. The lawsuit, filed in Harrison County, Texas District Court, alleges that Pfizer and […]

Retail investors crowd into Eli Lilly after weight-loss drug approval

reuters | November 17, 2023

By Bhanvi Satija and Amruta Khandekar (Reuters) – Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, […]

Wegovy’s heart benefits due to more than weight loss, Novo says

reuters | November 13, 2023

By Patrick Wingrove PHILADELPHIA (Reuters) -Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday. Early data from the Danish drugmaker’s Select trial released in August demonstrated that Wegovy, […]

U.S. FTC Disputes Over 100 Medical Patents Listed With FDA Including Asthma Inhalers

Cam White | November 7, 2023

By Diane Bartz and Patrick Wingrove WASHINGTON (Reuters) -The U.S. Federal Trade Commission (FTC) on Tuesday said it sent letters to medical device companies and drugmakers including AbbVie, AstraZeneca and Teva disputing the accuracy or relevance of 110 patents that could lead to delays in generic competition. Many of the patents at issue in the […]

Novo Nordisk to ‘Significantly’ Boost Obesity Drug Wegovy Doses Next Year in the U.S.

Cam White | November 2, 2023

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) – Novo Nordisk said on Thursday it will supply “significantly” more doses of Wegovy in the U.S. next year, even as it cautioned shortages of the weight-loss injection would continue in the short to medium term. The Danish drugmaker, which this year overtook LVMH as Europe’s most […]

Weight-Loss Drugs in Spotlight as Pharma Services Firms Rush to Snap up Business

Cam White | October 27, 2023

By Maggie Fick BARCELONA (Reuters) – Soaring demand for obesity drugs was in the spotlight at the world’s largest trade show for the pharmaceutical services industry this week, as it fuels a boom for firms that fill and assemble the self-injection pens. A surge in sales of Novo Nordisk’s drug Wegovy, which launched in the […]

Thermo Fisher Cuts Annual Profit Outlook Again on Weak Biotech Demand

Cam White | October 25, 2023

(Reuters) -Thermo Fisher Scientific on Wednesday cut its annual profit forecast for the second straight quarter following weak demand for its services used to make therapies and vaccines as well as higher raw material costs for the year. The medical equipment maker’s shares fell about 2% in premarket trading as it forecast annual adjusted profit […]

Next Page »